Cited by 288Lipid metabolism and disordersLipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism

Shachter, Neil S.·2001·Current Opinion in Lipidology

DOI 10.1097/00041433-200106000-00009

Open this paper in CoChat — free account

Abstract

Apolipoprotein (apo)C-I and apoC-III are constituents of HDL and of triglyceride-rich lipoproteins that slow the clearance of triglyceride-rich lipoproteins by a variety of mechanisms. ApoC-I is an inhibitor of lipoprotein binding to the LDL receptor, LDL receptor-related protein, and VLDL receptor. It also is the major plasma inhibitor of cholesteryl ester transfer protein, and appears to interfere directly with fatty acid uptake. ApoC-III also interferes with lipoprotein particle clearance, but its principal role is as an inhibitor of lipolysis, both through the biochemical inhibition of lipoprotein lipase and by interfering with lipoprotein binding to the cell-surface glycosaminoglycan matrix where lipolytic enzymes and lipoprotein receptors reside. Variation in the expression of apoC-III has been credibly documented to have an important role in hypertriglyceridemia. Variation in the expression of apoC-I may also be important for hypertriglyceridemia under certain circumstances.

Integrity signals

Registry

Crossref · 10.1097/00041433-200106000-00009

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells
Plump, A. S., Smith, J. D., Hayek, T., Aalto-Setälä, K., Walsh, A., Verstuyft, J. G., Rubin, E. M., & Breslow, J. L. (1992) · Cell · doi:10.1016/0092-8674(92)90362-g · Cited by 2,263
Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L. (1990) · Science · doi:10.1126/science.2167514 · Cited by 539
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424
Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.
Vu-Dac, N., Gervois, P., Torra, I. P., Fruchart, J. C., Kosykh, V, Kooistra, T., Princen, H. M., Dallongeville, J., & Staels, B. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1581 · Cited by 143

Show all 5 references

Research works printed but not linked: 93

Brown, 1969, J Biol Chem, 244, 5687, 10.1016/S0021-9258(18)63614-2 · DOI
Brown, 1970, J Biol Chem, 245, 6588, 10.1016/S0021-9258(18)62574-8 · DOI
Jong, 1999, Arterioscler Thromb Vasc Biol, 19, 472, 10.1161/01.ATV.19.3.472 · DOI · Paper page
Brown, 1972, Biochem Biophys Res Commun, 46, 375, 10.1016/S0006-291X(72)80115-3 · DOI
Havel, 1973, Biochemistry, 12, 1828, 10.1021/bi00733a026 · DOI
Landis, 1987, Am J Physiol, 252, G805
Carlson, 1976, Atherosclerosis, 23, 563, 10.1016/0021-9150(76)90016-2 · DOI
Le, 1988, J Lipid Res, 29, 669, 10.1016/S0022-2275(20)38512-6 · DOI · Paper page
Wang, 1985, J Clin Invest, 75, 384, 10.1172/JCI111711 · DOI
Dammerman, 1993, Proc Natl Acad Sci USA, 90, 4562, 10.1073/pnas.90.10.4562 · DOI
Aalto-Setala, 1992, J Clin Invest, 90, 1889, 10.1172/JCI116066 · DOI
de Silva, 1994, J Biol Chem, 269, 2324, 10.1016/S0021-9258(17)42171-5 · DOI
Maeda, 1994, J Biol Chem, 269, 23610, 10.1016/S0021-9258(17)31559-4 · DOI
Windler, 1980, J Biol Chem, 255, 8303, 10.1016/S0021-9258(19)70647-4 · DOI · Paper page
Quarfordt, 1982, J Biol Chem, 257, 14642, 10.1016/S0021-9258(18)33329-5 · DOI
Kowal, 1990, J Biol Chem, 265, 10771, 10.1016/S0021-9258(18)87014-4 · DOI · Paper page
Weisgraber, 1990, J Biol Chem, 265, 22453, 10.1016/S0021-9258(18)45726-2 · DOI
Windler, 1980, J Biol Chem, 255, 10464, 10.1016/S0021-9258(19)70487-6 · DOI
Sehayek, 1991, J Biol Chem, 266, 18259, 10.1016/S0021-9258(18)55263-7 · DOI · Paper page
Clavey, 1995, Arterioscler Thromb Vasc Biol, 15, 963, 10.1161/01.ATV.15.7.963 · DOI
Jong, 1999, Biochem J, 338, 281, 10.1042/0264-6021:3380281 · DOI
Albers, 1979, Artery, 5, 61
Sparks, 1989, J Lipid Res, 30, 1491, 10.1016/S0022-2275(20)38234-1 · DOI
Alaupovic, 1998, Anal Acad Nac Cs Ex Fis y Nat Buenos Aires Argentina, 50, 89
Moberly, 1999, Miner Electrolyte Metab, 25, 258, 10.1159/000057457 · DOI
Alaupovic, 1992, Diabetes, 41, 18, 10.2337/diab.41.2.S18 · DOI
Gervaise, 2000, Diabetologia, 43, 703, 10.1007/s001250051366 · DOI
Alaupovic, 1994, Arterioscler Thromb Vasc Biol, 14, 1906, 10.1161/01.ATV.14.12.1906 · DOI
Luc, 1996, J Lipid Res, 37, 508, 10.1016/S0022-2275(20)37594-5 · DOI · Paper page
Alaupovic, 1999, Atherosclerosis, 146, 369, 10.1016/S0021-9150(99)00151-3 · DOI
2000, Eur J Clin Invest, 30, 578, 10.1046/j.1365-2362.2000.00674.x · DOI
Bijvoet, 1996, J Lipid Res, 37, 640, 10.1016/S0022-2275(20)37605-7 · DOI
Batal, 2000, J Lipid Res, 41, 706, 10.1016/S0022-2275(20)32379-8 · DOI · Paper page
Talmud, 1997, Curr Opin Lipidol, 8, 154, 10.1097/00041433-199706000-00005 · DOI
Li, 1995, J Clin Invest, 96, 2601, 10.1172/JCI118324 · DOI · Paper page
Surguchov, 1996, Arterioscler Thromb Vasc Biol, 16, 941, 10.1161/01.ATV.16.8.941 · DOI
Groenendijk, 1999, J Lipid Res, 40, 1036, 10.1016/S0022-2275(20)33507-0 · DOI
Dallongeville, 2000, Atherosclerosis, 150, 149, 10.1016/S0021-9150(99)00362-7 · DOI
Waterworth, 2000, J Lipid Res, 41, 1103, 10.1016/S0022-2275(20)32016-2 · DOI
Waterworth, 1999, Circulation, 99, 1872, 10.1161/01.CIR.99.14.1872 · DOI
Esterbauer, 1999, Clin Chem, 45, 331, 10.1093/clinchem/45.3.331 · DOI
Kee, 1999, Atherosclerosis, 145, 187, 10.1016/S0021-9150(99)00066-0 · DOI
Dallinga-Thie, 1997, J Clin Invest, 99, 953, 10.1172/JCI119260 · DOI
Sijbrands, 1999, Arterioscler Thromb Vasc Biol, 19, 2722, 10.1161/01.ATV.19.11.2722 · DOI
Waterworth, 2000, Arterioscler Thromb Vasc Biol, 20, 2663, 10.1161/01.ATV.20.12.2663 · DOI
Hertz, 1995, J Biol Chem, 270, 13470, 10.1074/jbc.270.22.13470 · DOI
Clavey, 1999, Cell Physiol Biochem, 9, 139, 10.1159/000016311 · DOI
Attia, 2000, Atherosclerosis, 149, 427, 10.1016/S0021-9150(99)00337-8 · DOI
Ebara, 2000, J Clin Invest, 105, 1807, 10.1172/JCI8283 · DOI · Paper page
Wan, 2000, J Biol Chem, 275, 28285, 10.1074/jbc.M000934200 · DOI
Schoonjans, 1999, FEBS Lett, 452, 160, 10.1016/S0014-5793(99)00632-8 · DOI
Reddy, 1999, J Biol Chem, 274, 33050, 10.1074/jbc.274.46.33050 · DOI
Lehto, 1999, Diabetes, 48, 423, 10.2337/diabetes.48.2.423 · DOI
Shih, 2000, Diabetes, 49, 832, 10.2337/diabetes.49.5.832 · DOI
Forte, 1984, J Clin Invest, 74, 1601, 10.1172/JCI111576 · DOI
Lambert, 2000, Clin Chim Acta, 291, 19, 10.1016/S0009-8981(99)00193-X · DOI
Liu, 2000, Biochemistry, 39, 9201, 10.1021/bi0009441 · DOI
Liu, 2000, J Lipid Res, 41, 1760, 10.1016/S0022-2275(20)31969-6 · DOI
Eisenberg, 1984, J Lipid Res, 25, 1017, 10.1016/S0022-2275(20)37713-0 · DOI
Tornoci, 1993, J Lipid Res, 34, 1793, 10.1016/S0022-2275(20)35742-4 · DOI
Boyle, 1999, Biochim Biophys Acta, 1430, 302, 10.1016/S0167-4838(99)00009-6 · DOI
Breyer, 1999, J Lipid Res, 40, 1875, 10.1016/S0022-2275(20)34904-X · DOI
Zhang, 1992, Science, 258, 468, 10.1126/science.1411543 · DOI · Paper page
Maeda, 1994, J Biol Chem, 269, 23610, 10.1016/S0021-9258(17)31559-4 · DOI
Shachter, 1994, J Clin Invest, 93, 1683, 10.1172/JCI117151 · DOI
Shachter, 1996, J Clin Invest, 98, 846, 10.1172/JCI118857 · DOI
Ebara, 1997, J Clin Invest, 99, 2672, 10.1172/JCI119456 · DOI
Rahimkhani, 2000, Circulation, 102, II
Vergnes, 2000, Arterioscler Thromb Vasc Biol, 20, 2267, 10.1161/01.ATV.20.10.2267 · DOI
Hayek, 1995, J Clin Invest, 96, 2071, 10.1172/JCI118255 · DOI
Masucci-Magoulas, 1997, Science, 275, 391, 10.1126/science.275.5298.391 · DOI
Ishibashi, 1994, J Clin Invest, 93, 1885, 10.1172/JCI117179 · DOI
Phillips, 1993, Circulation, 88, 2762, 10.1161/01.CIR.88.6.2762 · DOI
Groot, 1991, Arterioscler Thromb, 11, 653, 10.1161/01.ATV.11.3.653 · DOI
Ginsberg, 1995, Arterioscler Thromb Vasc Biol, 15, 1829, 10.1161/01.ATV.15.11.1829 · DOI
Sharrett, 1995, Arterioscler Thromb Vasc Biol, 15, 2122, 10.1161/01.ATV.15.12.2122 · DOI
Bjorkegren, 2000, Circulation, 101, 227, 10.1161/01.CIR.101.3.227 · DOI
Bjorkegren, 1997, J Lipid Res, 38, 301, 10.1016/S0022-2275(20)37443-5 · DOI
Bjorkegren, 1998, J Lipid Res, 39, 1412, 10.1016/S0022-2275(20)32522-0 · DOI
Gautier, 2000, J Biol Chem, 275, 37504, 10.1074/jbc.M007210200 · DOI
Xu, 1999, J Lipid Res, 40, 50, 10.1016/S0022-2275(20)33338-1 · DOI
Seixas, 1999, Hum Biol, 71, 1001
Drigalenko, 1998, Neurology, 51, 131, 10.1212/WNL.51.1.131 · DOI
Medstrand, 2001, J Biol Chem, 276, 1896, 10.1074/jbc.M006557200 · DOI
Andersson, 1999, Arterioscler Thromb Vasc Biol, 19, 115, 10.1161/01.ATV.19.1.115 · DOI
Simonet, 1991, J Biol Chem, 266, 8651, 10.1016/S0021-9258(18)31491-1 · DOI
Allan, 1997, J Biol Chem, 272, 29113, 10.1074/jbc.272.46.29113 · DOI
Shih, 2000, J Biol Chem, 275, 31567, 10.1074/jbc.M005468200 · DOI · Paper page
van Ree, 1995, Biochem J, 305, 905, 10.1042/bj3050905 · DOI
Shachter, 1993, J Lipid Res, 34, 1699, 10.1016/S0022-2275(20)35732-1 · DOI
Jong, 1996, Arterioscler Thromb Vasc Biol, 16, 934, 10.1161/01.ATV.16.8.934 · DOI
Jong, 1996, J Clin Invest, 98, 2259, 10.1172/JCI119036 · DOI
Jong, 1998, J Clin Invest, 101, 145, 10.1172/JCI791 · DOI

Sorted by citations

Lipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2197 · Cited by 1,824
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism
Ginsberg, H. N. (2002) · Circulation · doi:10.1161/01.cir.0000035280.64322.31 · Cited by 255
Diabetic Dyslipidemia
Chahil, T. J., & Ginsberg, H. N. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.06.002 · Cited by 233
Identification of Rev-erbα as a physiological repressor of apoC-III gene transcription
Raspé, E., Duez, H., Mansén, A., Fontaine, C., Fiévet, C., Fruchart, J.-C., Vennström, B., & Staels, B. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200386-jlr200 · Cited by 183
Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.
Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032056 · Cited by 170
New insights into the mechanism of low high-density lipoprotein cholesterol in obesity
Wang, H., & Peng, D.-Q. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-176 · Cited by 140
Non-coding variability at the APOE locus contributes to the Alzheimer’s risk
Zhou, X., Chen, Y., Mok, K. Y., Kwok, T. C. Y., Mok, V. C. T., Guo, Q., Ip, F. C., Chen, Y., Mullapudi, N., Initiative, A. D. N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10945-z · Cited by 120
Automated multiplex LC-MS/MS assay for quantifying serum apolipoproteins A-I, B, C-I, C-II, C-III, and E with qualitative apolipoprotein E phenotyping
van den Broek, I., Romijn, F. P. H. T. M., Nouta, J., van der Laarse, A., Drijfhout, J. W., Smit, N. P. M., van der Burgt, Y. E. M., & Cobbaert, C. M. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.246702 · Cited by 105
Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.
Chunyu, Z., Christina, K., Katsunori, I., & Sacks, F. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p600011-jlr200 · Cited by 95
An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
Chan, D. C., Chen, M. M., Ooi, E. M. M., & Watts, G. F. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01678.x · Cited by 85
Biomedicinal Implications of High-Density Lipoprotein: Its Composition, Structure, Functions, and Clinical Applications
Cho, K.-H. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.7.393 · Cited by 74
Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
Chan, D. C., Watts, G. F., Nguyen, M. N., & Barrett, P. H. R. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000203519.25116.54 · Cited by 70
Apolipoproteins: New players in cancers
He, Y., Chen, J., Ma, Y., & Chen, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1051280 · Cited by 52
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans
Cohn, J. S., Batal, R., Tremblay, M., Jacques, H., Veilleux, L., Rodriguez, C., Mamer, O., & Davignon, J. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300209-jlr200 · Cited by 35

Authors: Shachter, N. S.
Affiliations: Columbia University (US)
Corresponding author: Shachter, Neil S.
Venue: Current Opinion in Lipidology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2001-06
Volume: 12
Issue: 3
Pages: 297-304
ISSN: 0957-9672 (ISSN-L)
DOI: 10.1097/00041433-200106000-00009
OpenAlex: W2334791394
Cited by: 288
References: 5
Citations by year: 2026: 3 · 2025: 1 · 2024: 4 · 2023: 5 · 2022: 7 · 2021: 6 · 2020: 6 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 7 · 2015: 15 · 2014: 11 · 2013: 15 · 2012: 15
FWCI: 3.84
Type: journal article
Language: en
Open access: closed
Locations: Current Opinion in Lipidology (publishedVersion)
PubMed (publishedVersion)
Funders: National Heart, Lung, and Blood Institute (P01HL057217, R01HL056232)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: apolipoprotein C-I, apolipoprotein C-III, lipoprotein metabolism, HDL cholesterol, triglyceride-rich lipoproteins, lipoprotein clearance, LDL receptor, LDL receptor-related protein, VLDL receptor, cholesteryl ester transfer protein, fatty acid uptake, lipoprotein lipase, lipolysis, hypertriglyceridemia
MeSH terms: Alleles, Animals, Apolipoproteins C, Gene Expression Regulation, Humans, Lipoproteins, Receptors, Immunologic, Receptors, LDL, Genetic Variation, Hypertriglyceridemia, Low Density Lipoprotein Receptor-Related Protein-1, Mice, Apolipoprotein C-I, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks